Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 358Fluorouracil 94Oxaliplatin 81Capecitabine 74130-nm albumin-bound paclitaxel 71Albumin-Bound Paclitaxel 70Radiotherapy 67Leucovorin 58Irinotecan 49Erlotinib Hydrochloride 47Cisplatin 44Bevacizumab 31pembrolizumab 30Radiosurgery 30Docetaxel 26Taxes 24Nivolumab 24Cetuximab 24Pancreaticoduodenectomy 20Drug Therapy 17folfirinox 16Cyclophosphamide 16Radiation 15Ipilimumab 13Endoscopic Ultrasound-Guided Fine Needle Aspiration 13Surgical Procedures, Operative 12Sorafenib 12Paclitaxel 12Neoadjuvant Therapy 12irinotecan sucrosofate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pancreatic Neoplasms × NP-G2-044 × Clear all
NCT03199586 2025-07-20

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals, Inc.

Phase 1 Completed
23 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡